Short Interest in Vicarious Surgical Inc. (NYSE:RBOT) Expands By 23.2%

Vicarious Surgical Inc. (NYSE:RBOT) was the recipient of a significant growth in short interest in February. As of February 13th, there was short interest totaling 383,672 shares, a growth of 23.2% from the January 29th total of 311,456 shares. Currently, 6.5% of the shares of the stock are short sold. Based on an average trading volume of 61,595 shares, the days-to-cover ratio is presently 6.2 days. Based on an average trading volume of 61,595 shares, the days-to-cover ratio is presently 6.2 days. Currently, 6.5% of the shares of the stock are short sold.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RBOT. XTX Topco Ltd acquired a new position in shares of Vicarious Surgical during the 4th quarter worth about $27,000. Dimensional Fund Advisors LP grew its stake in shares of Vicarious Surgical by 22.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 19,975 shares of the company’s stock valued at $110,000 after buying an additional 3,615 shares during the period. DNB Asset Management AS raised its position in Vicarious Surgical by 12.1% in the second quarter. DNB Asset Management AS now owns 29,199 shares of the company’s stock valued at $219,000 after purchasing an additional 3,154 shares during the period. Connective Capital Management LLC purchased a new stake in shares of Vicarious Surgical in the 3rd quarter valued at approximately $169,000. Finally, Geode Capital Management LLC lifted its stake in Vicarious Surgical by 26.0% during the 4th quarter. Geode Capital Management LLC now owns 40,494 shares of the company’s stock worth $88,000 after acquiring an additional 8,344 shares in the last quarter. Hedge funds and other institutional investors own 47.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on RBOT. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vicarious Surgical in a research report on Wednesday, January 21st. Wall Street Zen raised Vicarious Surgical from a “sell” rating to a “hold” rating in a research note on Sunday, February 8th. Finally, BTIG Research reissued a “neutral” rating on shares of Vicarious Surgical in a research report on Friday, December 12th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $7.00.

Vicarious Surgical Trading Down 53.2%

Shares of Vicarious Surgical stock traded down $1.02 during trading on Wednesday, hitting $0.90. 334,845 shares of the stock traded hands, compared to its average volume of 60,400. Vicarious Surgical has a 52-week low of $0.52 and a 52-week high of $13.75. The firm has a market cap of $5.89 million, a P/E ratio of -0.10 and a beta of 1.53. The stock’s fifty day simple moving average is $2.19 and its 200 day simple moving average is $3.90.

Vicarious Surgical Company Profile

Vicarious Surgical develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.

The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology.